00:27 , Jun 22, 2019 |  BC Extra  |  Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma  Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
06:32 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Cancer Prevention starts Phase II of CPP-1x to prevent gastric cancer

Cancer Prevention Pharmaceuticals Inc. (Tucson, Ariz.) began a Phase II trial of CPP-1X to prevent gastric cancer in patients with precancerous gastric lesions. The double-blind, placebo-controlled trial will evaluate 500 mg daily oral CPP-1X for...
20:38 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

Cancer Prevention Pharmaceuticals Inc. (Tucson, Ariz.) said an IDMC recommended continuation of the Phase III CPP FAP-310 trial evaluating eflornithine/sulindac (DFMO/sulindac, CPP-1X/sulindac) to treat familial adenomatous polyposis (FAP). The product is a combination of eflornithine...
22:34 , Apr 7, 2017 |  BioCentury  |  Finance

Right place, right time

The takeout of Vtesse Inc. by Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) filled gaps for each company while giving Vtesse investors an exit and a share of any upside. The Vtesse team will get the resources it...
20:41 , Nov 4, 2016 |  BC Week In Review  |  Financial News

Cancer Prevention Pharmaceuticals withdraws IPO

Cancer Prevention withdrew its IPO on NYSE MKT, citing market conditions. Last December, it filed to raise up to $28.8 million. Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. ...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)

Infectious disease INDICATION: Chikungunya virus; viral infection Studies in mammalian cell culture, fruit flies and zebrafish suggest promoting SAT1 expression or inhibiting ODC could help treat Chikungunya, Sindbis and Zika viral infections. In a hamster...